e-Drug3D

1828

MIDOSTAURIN

INN
MIDOSTAURIN

cas 120685-11-2

CLASS

ANTINEOPLASTIC
TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) OR AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM)
MULTIKINASE TYROSINE KINASE INHIBITOR (FLT3, FLT3 MUTANT KINASES (ITD AND TKD), KIT (WILD TYPE AND D816V MUTANT), PDGFR ALPHA/BETA, VEGFR2, AS WELL AS MEMBERS OF THE SERINE/THREONINE KINASE PKC (PROTEIN KINASE C) FAMILY)

ROUTE (list)

ORAL

ATC code

L01EX10

PK parameters

Tmax 2 HOUR
VD 95.2 LITER
PPB 99.8 PERCENT
t1/2 21 HOUR

Target

TARGET FLT3 KINASE
FLT3 MUTANT KINASES
KIT
PDGFR
VEGFR2
SERINE/THREONINE KINASE PKC

PDB
4NCT (HUMAN DYRK1A IN COMPLEX WITH PKC412)

Ligand code = 2K2 (link to the list of PDB complexes)

Download experimental 3D coordinates of 2K2 with added hydrogens

DrugCentral

Receptor-type tyrosine-protein kinase FLT3 UNIPROT P36888 FLT3

Download SDF file

Benzamide, N-[(9S,10R,11R,13R)-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl]-N-methyl-

Formula:
C35H30N4O4

Calculated chemical properties:

MW 570.63
NB_atoms 43
XLogP 5.91
PSA 55.411
NB_HD 1
NB_HA 8
fsp3 0.26
Lipinski(0=no;1=yes) 0

FDA
NDA 207997 (label) INN (MIDOSTAURIN) RYDAPT (NOVARTIS) APPROVAL= AP YEAR= 2017
NDA 215834 (pdf not found) INN (MIDOSTAURIN) MIDOSTAURIN (LOTUS PHARM CO LTD) APPROVAL= TA YEAR= 2022
NDA 216015 (pdf not found) INN (MIDOSTAURIN) MIDOSTAURIN (LUPIN) APPROVAL= AP YEAR= 2024
NDA 216076 (pdf not found) INN (MIDOSTAURIN) MIDOSTAURIN (TEVA PHARMS) APPROVAL= AP YEAR= 2024 DISCONTINUED
NDA 215921 (pdf not found) INN (MIDOSTAURIN) MIDOSTAURIN (DR REDDYS) APPROVAL= AP YEAR= 2024